NICE reverses decision on access to new blood cancer drug

NHS patients in England and Wales with chronic lymphocytic leukaemia (CLL) could soon benefit from Gazyvaro, which has today been given the provisional green light by the National Institute for Health and Care Excellence (NICE).

Source: Pharmacy Europe - December 3, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Oncology Patient care Policy & practice cll Gazyvaro Latest News nice progression free survival type II anti-CD20 monoclonal antibody Source Type: news